胰腺导管腺癌切除术中预后因素的时变影响。

IF 7.2 1区 医学 Q1 ONCOLOGY
Ammar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, Omar Mahmud, Iris W J M van Goor, Joseph R Habib, Paul Andel, Brady A Campbell, Thijs J Schouten, Fabio Bagante, Nabiha A Mughal, Thomas F Stoop, Kelly J Lafaro, Richard A Burkhart, William R Burns, D Brock Hewitt, Greg D Sacks, Hjalmar C van Santvoort, Marcel den Dulk, Freek Daams, J Sven D Mieog, Martijn W J Stommel, Gijs A Patijn, Ignace de Hingh, Sebastiaan Festen, Maarten W Nijkamp, Joost M Klaase, Daan J Lips, Jan H Wijsman, Erwin van der Harst, Eric Manusama, Casper H J van Eijck, Bas Groot Koerkamp, Geert Kazemier, Olivier R Busch, I Quintus Molenaar, Lois A Daamen, Marc G Besselink, Jin He, Christopher L Wolfgang
{"title":"胰腺导管腺癌切除术中预后因素的时变影响。","authors":"Ammar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, Omar Mahmud, Iris W J M van Goor, Joseph R Habib, Paul Andel, Brady A Campbell, Thijs J Schouten, Fabio Bagante, Nabiha A Mughal, Thomas F Stoop, Kelly J Lafaro, Richard A Burkhart, William R Burns, D Brock Hewitt, Greg D Sacks, Hjalmar C van Santvoort, Marcel den Dulk, Freek Daams, J Sven D Mieog, Martijn W J Stommel, Gijs A Patijn, Ignace de Hingh, Sebastiaan Festen, Maarten W Nijkamp, Joost M Klaase, Daan J Lips, Jan H Wijsman, Erwin van der Harst, Eric Manusama, Casper H J van Eijck, Bas Groot Koerkamp, Geert Kazemier, Olivier R Busch, I Quintus Molenaar, Lois A Daamen, Marc G Besselink, Jin He, Christopher L Wolfgang","doi":"10.1093/jnci/djaf196","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prognostic factors in resected pancreatic ductal adenocarcinoma (PDAC) have been determined under the assumption that hazard ratios (HRs) remain static. However, PDAC is a dynamic disease with evolving conditional survival. The aim of this study was to determine if the impact of prognostic factors in PDAC is time-varying.</p><p><strong>Methods: </strong>This was a multicenter, retrospective cohort study of the prospectively maintained Dutch Pancreatic Cancer Recurrence Database and New York University and Johns Hopkins Hospital Institutional Databases. Patients with complete macroscopic resection of histopathologically proven PDAC between 2014 and 2019 and available follow-up data were included. The time-varying impact of prognostic factors identified by univariable cox-regression was modelled using Aalen's Additive Regression Models (Aalen's models) and visualized as plots of cumulative hazard.</p><p><strong>Results: </strong>3104 patients were included, of whom 938 (30.2%) received neoadjuvant therapy (NAT) while the rest underwent upfront surgery (US). 201 (6.5%) patients achieved observed long-term survival (>5 years). Aalen's models showed that lymphovascular invasion, perineural invasion, and nodal disease were prognostic up to 2 years post-operatively. At varying points thereafter, these variables lost their impact in the NAT but not US patients. Similarly, during the 4th year of follow-up, American Society of Anesthesiology scores became impactful in the NAT but not in the US patients.</p><p><strong>Interpretation: </strong>The impact of prognostic factors in resected PDAC across NAT and US patients is time-varying. Our results suggest that aggressive disease drives early mortality but, after NAT, tumor-biological factors lose prognostic importance to frailty and comorbidities over time.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma.\",\"authors\":\"Ammar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, Omar Mahmud, Iris W J M van Goor, Joseph R Habib, Paul Andel, Brady A Campbell, Thijs J Schouten, Fabio Bagante, Nabiha A Mughal, Thomas F Stoop, Kelly J Lafaro, Richard A Burkhart, William R Burns, D Brock Hewitt, Greg D Sacks, Hjalmar C van Santvoort, Marcel den Dulk, Freek Daams, J Sven D Mieog, Martijn W J Stommel, Gijs A Patijn, Ignace de Hingh, Sebastiaan Festen, Maarten W Nijkamp, Joost M Klaase, Daan J Lips, Jan H Wijsman, Erwin van der Harst, Eric Manusama, Casper H J van Eijck, Bas Groot Koerkamp, Geert Kazemier, Olivier R Busch, I Quintus Molenaar, Lois A Daamen, Marc G Besselink, Jin He, Christopher L Wolfgang\",\"doi\":\"10.1093/jnci/djaf196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prognostic factors in resected pancreatic ductal adenocarcinoma (PDAC) have been determined under the assumption that hazard ratios (HRs) remain static. However, PDAC is a dynamic disease with evolving conditional survival. The aim of this study was to determine if the impact of prognostic factors in PDAC is time-varying.</p><p><strong>Methods: </strong>This was a multicenter, retrospective cohort study of the prospectively maintained Dutch Pancreatic Cancer Recurrence Database and New York University and Johns Hopkins Hospital Institutional Databases. Patients with complete macroscopic resection of histopathologically proven PDAC between 2014 and 2019 and available follow-up data were included. The time-varying impact of prognostic factors identified by univariable cox-regression was modelled using Aalen's Additive Regression Models (Aalen's models) and visualized as plots of cumulative hazard.</p><p><strong>Results: </strong>3104 patients were included, of whom 938 (30.2%) received neoadjuvant therapy (NAT) while the rest underwent upfront surgery (US). 201 (6.5%) patients achieved observed long-term survival (>5 years). Aalen's models showed that lymphovascular invasion, perineural invasion, and nodal disease were prognostic up to 2 years post-operatively. At varying points thereafter, these variables lost their impact in the NAT but not US patients. Similarly, during the 4th year of follow-up, American Society of Anesthesiology scores became impactful in the NAT but not in the US patients.</p><p><strong>Interpretation: </strong>The impact of prognostic factors in resected PDAC across NAT and US patients is time-varying. Our results suggest that aggressive disease drives early mortality but, after NAT, tumor-biological factors lose prognostic importance to frailty and comorbidities over time.</p>\",\"PeriodicalId\":14809,\"journal\":{\"name\":\"JNCI Journal of the National Cancer Institute\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JNCI Journal of the National Cancer Institute\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jnci/djaf196\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Journal of the National Cancer Institute","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnci/djaf196","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在假设风险比(hr)保持不变的情况下,已经确定了切除胰腺导管腺癌(PDAC)的预后因素。然而,PDAC是一种动态疾病,具有不断进化的条件生存。本研究的目的是确定PDAC预后因素的影响是否随时间变化。方法:这是一项多中心,回顾性队列研究,前瞻性维护荷兰胰腺癌复发数据库和纽约大学和约翰霍普金斯医院机构数据库。纳入2014 - 2019年经组织病理学证实的PDAC宏观完全切除患者及现有随访数据。单变量cox回归确定的预后因素的时变影响使用Aalen的加性回归模型(Aalen模型)建模,并将其可视化为累积风险图。结果:纳入3104例患者,其中938例(30.2%)接受了新辅助治疗(NAT),其余患者接受了术前手术(US)。201例(6.5%)患者达到观察到的长期生存期(50年)。Aalen的模型显示,淋巴血管侵犯、神经周围侵犯和淋巴结疾病是术后2年的预后因素。在此后的不同时间点,这些变量在NAT中失去了影响,但在美国患者中没有。同样,在第4年的随访中,美国麻醉学学会评分对NAT有影响,但对美国患者没有影响。结论:在NAT和美国的PDAC切除患者中,预后因素的影响是时变的。我们的研究结果表明,侵袭性疾病驱动早期死亡,但在NAT后,肿瘤生物学因素随着时间的推移失去了对虚弱和合并症的预后重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma.

Background: Prognostic factors in resected pancreatic ductal adenocarcinoma (PDAC) have been determined under the assumption that hazard ratios (HRs) remain static. However, PDAC is a dynamic disease with evolving conditional survival. The aim of this study was to determine if the impact of prognostic factors in PDAC is time-varying.

Methods: This was a multicenter, retrospective cohort study of the prospectively maintained Dutch Pancreatic Cancer Recurrence Database and New York University and Johns Hopkins Hospital Institutional Databases. Patients with complete macroscopic resection of histopathologically proven PDAC between 2014 and 2019 and available follow-up data were included. The time-varying impact of prognostic factors identified by univariable cox-regression was modelled using Aalen's Additive Regression Models (Aalen's models) and visualized as plots of cumulative hazard.

Results: 3104 patients were included, of whom 938 (30.2%) received neoadjuvant therapy (NAT) while the rest underwent upfront surgery (US). 201 (6.5%) patients achieved observed long-term survival (>5 years). Aalen's models showed that lymphovascular invasion, perineural invasion, and nodal disease were prognostic up to 2 years post-operatively. At varying points thereafter, these variables lost their impact in the NAT but not US patients. Similarly, during the 4th year of follow-up, American Society of Anesthesiology scores became impactful in the NAT but not in the US patients.

Interpretation: The impact of prognostic factors in resected PDAC across NAT and US patients is time-varying. Our results suggest that aggressive disease drives early mortality but, after NAT, tumor-biological factors lose prognostic importance to frailty and comorbidities over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
17.00
自引率
2.90%
发文量
203
审稿时长
4-8 weeks
期刊介绍: The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信